TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2388132

Group type: EXPERIMENTAL
Intervention: Semi-elemental formula (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Milk containing soy proteins and vegetable oils (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Common cow's-milk formula (Group C)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Groups A and B (after 4 weeks challenge with cow's milk)
Number of subjects: 90
Study: 466336

Group type: EXPERIMENTAL
Intervention: Gutter treatment for ingrowing toenails
Number of subjects: 61

Group type: COMPARATOR
Intervention: Wedge resection procedure
Number of subjects: 61

Group type: COMPARATOR
Intervention: Toenail avulsion
Number of subjects: 61
Study: 30592144

Group type: EXPERIMENTAL
Intervention: Podcast videos on airway management
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional one-to-one hands-on training
Number of subjects: 34
Study: 28992899

Group type: EXPERIMENTAL
Intervention: Online cognitive-behavioral therapy (CBT) plus three therapist support calls
Number of subjects: 25

Group type: COMPARATOR
Intervention: Online cognitive-behavioral therapy (CBT) without therapist support calls
Number of subjects: 25
Study: 25882864

Group type: EXPERIMENTAL
Intervention: Weight reduction through 6 months hypocaloric dieting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natriuretic peptide receptor type C mRNA expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natriuretic peptide receptor type A mRNA expression
Number of subjects: 0
Study: 24062325

Group type: EXPERIMENTAL
Intervention: Bright Bodies (BB) Healthy Lifestyle Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard clinical care (CC)
Number of subjects: 0
Study: 20864417

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (90-minute infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone (1-time bolus)
Number of subjects: 0
Study: 19407805

Group type: EXPERIMENTAL
Intervention: Aspirin at bedtime (100 mg/day)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Aspirin on awakening (100 mg/day)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Nonpharmacological hygienic-dietary recommendations
Number of subjects: 244
Study: 17606561

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (12 U/kg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo saline injections
Number of subjects: 33
Study: 15128894

Group type: EXPERIMENTAL
Intervention: Concomitant cisplatin (100 mg/m² on days 1, 22, and 43) with radiotherapy (66 Gy over 6.5 weeks)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Radiotherapy alone (66 Gy over 6.5 weeks)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Concomitant cisplatin with radiotherapy
Number of subjects: 334

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 334
Study: 11922401

Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg, 20 mg, 30 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Triprolidine 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ebastine 30 mg
Number of subjects: 10
Study: 9620515

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10087864

Group type: EXPERIMENTAL
Intervention: Dependent confidence in two hypotheses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Encouraging consideration of the alternative
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Independent confidence with intervention to produce complementarity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Independent confidence without intervention
Number of subjects: 0
Study: 2752891

Group type: EXPERIMENTAL
Intervention: Abnormal glucose tolerance (IGT and diabetes)
Number of subjects: 1422

Group type: EXPERIMENTAL
Intervention: IGT
Number of subjects: 1422

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 1422

Group type: COMPARATOR
Intervention: Normoglycaemics
Number of subjects: 1422

Group type: COMPARATOR
Intervention: IGTs
Number of subjects: 1422

Group type: EXPERIMENTAL
Intervention: Initial IGTs
Number of subjects: 1422

Group type: COMPARATOR
Intervention: Initial normoglycaemics
Number of subjects: 1422

Group type: EXPERIMENTAL
Intervention: Determinants of worsening glucose tolerance
Number of subjects: 1422
Study: 320827

Group type: EXPERIMENTAL
Intervention: Lofepramine (70 mg t.i.d.)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Imipramine (50 mg t.i.d.)
Number of subjects: 62
Study: 31399845

Group type: EXPERIMENTAL
Intervention: Canagliflozin (100/300 mg once daily)
Number of subjects: 10142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10142
Study: 28007971

Group type: EXPERIMENTAL
Intervention: Educational tool (spiral-bound, laminated booklet with safety messages), plug-in CO detector, and 9V battery
Number of subjects: 299

Group type: COMPARATOR
Intervention: One page flyer on CO poisoning prevention
Number of subjects: 299
Study: 26844281

Group type: EXPERIMENTAL
Intervention: R213G heterozygotes (213RG)
Number of subjects: 4498

Group type: COMPARATOR
Intervention: Non-diabetic subjects
Number of subjects: 4498
Study: 23790987

Group type: EXPERIMENTAL
Intervention: Stigmatizing campaigns
Number of subjects: 1085

Group type: COMPARATOR
Intervention: Neutral campaigns
Number of subjects: 1085
Study: 21448363

Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with fluorouracil plus cisplatin (PCF)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Oxaliplatin combined with fluorouracil plus leucovorin (FOLFOX‐4)
Number of subjects: 94
Study: 19335936

Group type: EXPERIMENTAL
Intervention: Intravenous synthetic THC (2.5 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 16750125

Group type: EXPERIMENTAL
Intervention: One drug taken at bedtime
Number of subjects: 123

Group type: COMPARATOR
Intervention: All drugs taken in the morning
Number of subjects: 123
Study: 15280529

Group type: EXPERIMENTAL
Intervention: Pre-emptive treatment (angioplasty and/or open surgery)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard monitoring and intervention based on clinical criteria (control group)
Number of subjects: 79
Study: 11315820

Group type: COMPARATOR
Intervention: LP 100%
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: LP 50%
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: LP 75%
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Reduction in premeal insulin dose
Number of subjects: 8
Study: 9134643

Group type: EXPERIMENTAL
Intervention: High-intensity coumarin therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-intensity coumarin therapy
Number of subjects: 10
Study: 8185424

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 0.625 mg/d
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 1.25 mg/d
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 3408013

Group type: EXPERIMENTAL
Intervention: Bioclusive transparent polyurethane (TP) dressing
Number of subjects: 598

Group type: COMPARATOR
Intervention: Cotton gauze (CG) dressing
Number of subjects: 598
Study: 31758164

Group type: EXPERIMENTAL
Intervention: High milk intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened soft drink intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noncaloric soft drink intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 26291918

Group type: EXPERIMENTAL
Intervention: 0.50% DHEA (prasterone) ovules administered intravaginally daily for 12 weeks
Number of subjects: 0
Study: 23599120

Group type: EXPERIMENTAL
Intervention: 3 to 12 mg kg(‐1) per day of iron supplementation based on the ZnPP/H
Number of subjects: 81

Group type: COMPARATOR
Intervention: 2.2 mg kg(‐1) per day of ferrous sulfate (control)
Number of subjects: 81
Study: 21883322

Group type: EXPERIMENTAL
Intervention: AST-120 2 g tds
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 19214545

Group type: EXPERIMENTAL
Intervention: Unilateral ovarian drilling
Number of subjects: 44

Group type: COMPARATOR
Intervention: Bilateral ovarian drilling
Number of subjects: 44
Study: 16463240

Group type: EXPERIMENTAL
Intervention: Highly motivated group
Number of subjects: 64

Group type: COMPARATOR
Intervention: Minimally motivated group
Number of subjects: 64
Study: 15343198

Group type: EXPERIMENTAL
Intervention: Brief motivational interview (MI)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 152
Study: 10789748

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced magnetic resonance imaging
Number of subjects: 52

Group type: COMPARATOR
Intervention: Surgical exploration
Number of subjects: 52
Study: 10168262

Group type: EXPERIMENTAL
Intervention: Supermarket intervention including flyers, coupons, and signage
Number of subjects: 960

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 960
Study: 8230988

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) administered intravenously (dose 100 m/kg b.w.)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no MgSO4)
Number of subjects: 100
Study: 3633631

Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no pancreatic enzyme therapy)
Number of subjects: 20
Study: 31682878

Group type: EXPERIMENTAL
Intervention: SM-VAP patients receiving early adequate therapy (n=70, 68.6%)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: SM-VAP patients
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Risk factors for Day-30 mortality
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Adequate treatment (monotherapy or combination of antimicrobials)
Number of subjects: 102
Study: 29635119

Group type: EXPERIMENTAL
Intervention: Caregiving
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Competition
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study: 26803589

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (carbohydrate <40 g/day)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Low-fat diet (<30% energy from fat, <7% from saturated fat)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 148
Study: 24881463

Group type: EXPERIMENTAL
Intervention: Exemestane plus ovarian suppression
Number of subjects: 4690

Group type: COMPARATOR
Intervention: Tamoxifen plus ovarian suppression
Number of subjects: 4690
Study: 22237064

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 737

Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 737
Study: 20051257

Group type: EXPERIMENTAL
Intervention: Wujijing Oral Liquid (WJJ) 10mL twice daily for 2 menstrual cycles
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 18038179

Group type: EXPERIMENTAL
Intervention: Diode laser therapy (810 nm)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) therapy
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 7
Study: 16395994

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0
Study: 12759802

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: All antipsychotic medications
Number of subjects: 49
Study: 10553856

Group type: EXPERIMENTAL
Intervention: 1 mg/kg succinylcholine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.5 mg/kg succinylcholine
Number of subjects: 50
Study: 8688343

Group type: EXPERIMENTAL
Intervention: Active pastilles containing amphotericin, polymyxin and tobramycin, suck four times daily
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study: 12797050

Group type: EXPERIMENTAL
Intervention: Early amniocentesis
Number of subjects: 650

Group type: COMPARATOR
Intervention: Chorionic villus sampling (CVS)
Number of subjects: 650
Study: 6823893

Group type: EXPERIMENTAL
Intervention: 7-day record (7DR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 3-day record (3DR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1-day record (1DR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Food frequency form
Number of subjects: 40
Study: 31039165

Group type: COMPARATOR
Intervention: Facility-based screening (sputum Xpert MTB/RIF performed on all patients with TB symptoms)
Number of subjects: 3755

Group type: EXPERIMENTAL
Intervention: Contact tracing (household tracing and monetary incentives for screening contacts of TB patients)
Number of subjects: 3755
Study: 30206197

Group type: EXPERIMENTAL
Intervention: Hand massage (2 times for 5 minutes each)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual nursing interventions
Number of subjects: 60
Study: 25864623

Group type: EXPERIMENTAL
Intervention: Vitamin D (vitamin D3 [cholecalciferol], 2000 IU/d)
Number of subjects: 25875

Group type: EXPERIMENTAL
Intervention: Marine omega-3 fatty acids (Omacor(®) fish oil, 1 g/d)
Number of subjects: 25875

Group type: COMPARATOR
Intervention: Placebo (for both vitamin D and omega-3)
Number of subjects: 25875
Study: 24196538

Group type: EXPERIMENTAL
Intervention: Vicryl suture
Number of subjects: 70

Group type: COMPARATOR
Intervention: Titanium tacker
Number of subjects: 70
Study: 21987240

Group type: EXPERIMENTAL
Intervention: Oral moxifloxacin 400 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous moxifloxacin 400 mg
Number of subjects: 12
Study: 20541286

Group type: EXPERIMENTAL
Intervention: Support Vector Machine algorithm using combined brain imaging and biomarkers
Number of subjects: 737
Study: 17141357

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cisplatin and vinorelbine
Number of subjects: 482

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 482
Study: 15905296

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg/day)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Metformin plus flutamide (62.5 mg/day)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Oral contraception (OC) monotherapy
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Oral contraception plus flutamide-metformin
Number of subjects: 118
Study: 12569142

Group type: EXPERIMENTAL
Intervention: 9-cis-retinoic acid (100 mg daily for 3 months)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid (1 mg/kg) + alpha-tocopherol (1200 IU) for 3 months
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study: 10554530

Group type: COMPARATOR
Intervention: Amifostine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Selenium
Number of subjects: 30
Study: 8736145

Group type: EXPERIMENTAL
Intervention: Alzheimer's dementia (AD)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Parkinson's disease (PD)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (chronic depression)
Number of subjects: 29
Study: 1759096

Group type: EXPERIMENTAL
Intervention: Oral administration of tincture of belladonna (0.01 mg/kg weight of atropine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo syrup containing no belladonna
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both belladonna and placebo
Number of subjects: 20
Study: 7137431

Group type: EXPERIMENTAL
Intervention: Parental consent regulation for neonatal screening
Number of subjects: 0
Study: 31773209

Group type: EXPERIMENTAL
Intervention: Cherry flavored e-liquid (24 mg/ml)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Vanilla flavored e-liquid (24 mg/ml)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All flavored e-liquids
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Menthol flavored e-liquid (24 mg/ml)
Number of subjects: 18
Study: 30684522

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (unspecific MR/GR agonist)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fludrocortisone (specific MR agonist)
Number of subjects: 80
Study: 28760368

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No adjuvant chemotherapy (NACG)
Number of subjects: 60
Study: 25184801

Group type: EXPERIMENTAL
Intervention: Solid AFO
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dynamic AFO
Number of subjects: 10

Group type: COMPARATOR
Intervention: Without AFO
Number of subjects: 10
Study: 23297009

Group type: EXPERIMENTAL
Intervention: Attributional bias task during fMRI scanning
Number of subjects: 71
Study: 22050610

Group type: EXPERIMENTAL
Intervention: Closure of the external fascia (group A)
Number of subjects: 162

Group type: COMPARATOR
Intervention: No closure of the external fascia (group B)
Number of subjects: 162
Study: 19919718

Group type: EXPERIMENTAL
Intervention: Regular aerobic physical exercise (walking 10 minutes, aerobic exercise 30 minutes, stretching 10 minutes, relaxation exercise 10 minutes, three sessions per week)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Activities of daily living (bathing, dressing, eating, walking) without counselling from a physical therapist
Number of subjects: 64
Study: 16619524

Group type: EXPERIMENTAL
Intervention: Gleason pattern 3 (G3) tumors
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Gleason pattern 4 (G4) tumors
Number of subjects: 17

Group type: COMPARATOR
Intervention: Comparison between Gleason patterns 3 and 4
Number of subjects: 17

Group type: COMPARATOR
Intervention: Comparison of Gleason grades within one cancer
Number of subjects: 17
Study: 15354946

Group type: EXPERIMENTAL
Intervention: Dosulepin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study: 11139961

Group type: EXPERIMENTAL
Intervention: dofetilide (500 micrograms bid)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: sotalol (160 mg bid)
Number of subjects: 57
Study: 9052343

Group type: EXPERIMENTAL
Intervention: Propafenone 2 mg/kg over 30 minutes, followed by oral propafenone 150 mg 3 times daily
Number of subjects: 136

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Propafenone 150 mg 3 times daily
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 136
Study: 8111802

Group type: EXPERIMENTAL
Intervention: 10 mg torsemide
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 20 mg torsemide
Number of subjects: 70

Group type: COMPARATOR
Intervention: 40 mg furosemide
Number of subjects: 70
Study: 2427858

Group type: EXPERIMENTAL
Intervention: 200 mg celiprolol for 3 weeks, then increased to 300 mg or added diuretic for another 3 weeks
Number of subjects: 2694

Group type: EXPERIMENTAL
Intervention: 300 mg celiprolol
Number of subjects: 2694

Group type: EXPERIMENTAL
Intervention: Diuretic added to treatment
Number of subjects: 2694

Group type: EXPERIMENTAL
Intervention: Celiprolol treatment
Number of subjects: 2694

Group type: EXPERIMENTAL
Intervention: Celiprolol administered for up to 6 weeks
Number of subjects: 2694
Study: 31482201

Group type: EXPERIMENTAL
Intervention: Complement pathway inhibition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31606288

Group type: EXPERIMENTAL
Intervention: Mid-treatment MRI showing complete response (mCR)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Mid-treatment MRI showing partial response (mPR)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Stable/progressive disease (SD/PD)
Number of subjects: 519
Study: 29946106

Group type: EXPERIMENTAL
Intervention: Active deep rTMS (H1 coil, 6012 pulses, 18 Hz, 120% of resting motor threshold)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham deep rTMS
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Active deep rTMS
Number of subjects: 52
Study: 27496103

Group type: EXPERIMENTAL
Intervention: kJ labelling alone
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: kJ labelling with social marketing campaign
Number of subjects: 713

Group type: COMPARATOR
Intervention: kJ labelling
Number of subjects: 713
Study: 24075889

Group type: EXPERIMENTAL
Intervention: Linaclotide (290 μg, oral, once daily for 12 weeks)
Number of subjects: 1602

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1602

Group type: EXPERIMENTAL
Intervention: Linaclotide
Number of subjects: 1602
Study: 22858390

Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 1001
Study: 20392890

Group type: EXPERIMENTAL
Intervention: Red tomato paste (200 g/d providing 16 mg lycopene)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Purified lycopene (16 mg/d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Yellow tomato paste (200 g/d providing 0 mg lycopene)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18923312

Group type: EXPERIMENTAL
Intervention: 0.4 mg intrathecal morphine (M-group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal saline (P-group)
Number of subjects: 46
Study: 16443789

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 89
Study: 12808527

Group type: EXPERIMENTAL
Intervention: Group-based multidisciplinary cognitive behavioral therapy
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Individual therapy cognitive behavioral therapy
Number of subjects: 113
Study: 11304027

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) infusion (0.5 microg/kg per min for 20 min)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) infusion
Number of subjects: 16
Study: 8970355

Group type: EXPERIMENTAL
Intervention: Dobutamine (5 micrograms/kg/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dopamine (5 micrograms/kg/min)
Number of subjects: 10
Study: 1365868

Group type: EXPERIMENTAL
Intervention: Vitamin B-6 supplementation (20 mg pyridoxine HCL daily for 3 months)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 6532126

Group type: EXPERIMENTAL
Intervention: Indomethacin (4 X 25 mg, orally)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium salicylate (4 X 250 mg, orally)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg) plus sodium salicylate (250 mg) (Pelsonin, 4 X 1 capsules)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (baseline gastric bleeding)
Number of subjects: 0